The companies will offer CDI's human induced pluripotent stem cell-derived tissue cells with Nanion's ion channel drug discovery and screening platform.
The firms will comarket AATI's automated CE systems for quality control analysis of nucleic acids in Illumina's next-generation sequencing workflows.
The companies will market Angle's Parsortix system for harvesting circulating tumor cells with Qiagen's liquid biopsy product portfolio.
The companies will market Agena's MassArray Dx system with HeartGenetics' HeartDecode genetic testing software and cardiovascular assays.
Separately, FlowJo and Cytapex Bioinformatics said they have partnered to provide bioinformatics consulting and services for flow cytometry data analysis.
The companies will develop a portfolio of indexed adapters specifically designed for multiplex NGS and optimized for use on Illumina systems such as the NovaSeq.
The companies will market Proteos' protein production services alongside Protea's bioanalytical services.
The agreement combines TTP's Mosquito with AATI's Fragment Analyzer to improve library preparation for next-generation sequencing.
The arrangement will allow Illumina to market and promote Kailos' research solutions for pharmacogenetic target enrichment.
Under a new co-exclusive agreement, Thermo Fisher will be able to sell 908's ZipChip platform alongside its HRAM mass spec instruments.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.